e-learning
resources
Copenhagen 2005
Sunday 18.09.2005
Lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Thrombin activatable fibrinolytic inhibitor in sera from NSCLC patients
D. Dworakowska, A. Kulwas, M. Lapinski, D. Tomaszewski, R. Dworakowski, J. Skokowski, E. Zekanowska, D. Rosc, E. Czestochowska (Gdansk, Bydgoszcz, Poland)
Source:
Annual Congress 2005 - Lung cancer
Session:
Lung cancer
Session type:
Thematic Poster Session
Number:
667
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Dworakowska, A. Kulwas, M. Lapinski, D. Tomaszewski, R. Dworakowski, J. Skokowski, E. Zekanowska, D. Rosc, E. Czestochowska (Gdansk, Bydgoszcz, Poland). Thrombin activatable fibrinolytic inhibitor in sera from NSCLC patients. Eur Respir J 2005; 26: Suppl. 49, 667
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Increased intraalveolar levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with interstitial lung disease
Source: Eur Respir J 2002; 20: Suppl. 38, 586s
Year: 2002
Expression of thrombin-activatable fibrinolysis inhibitor (TAFI) by lung cancer cell lines
Source: Eur Respir J 2002; 20: Suppl. 38, 585s
Year: 2002
Intraalveolar levels of tenascin C and thrombin-activatable fibrinolysis inhibitor in interstitial lung diseases
Source: Eur Respir J 2003; 22: Suppl. 45, 83s
Year: 2003
Role of thrombin-activatable fibrinolysis inhibitor in bronchial asthma
Source: Annual Congress 2009 - Animal models of airways inflammation
Year: 2009
Role of thrombin-activatable fibrinolysis inhibitor in lipopolysaccharide-induced acute lung injury
Source: Annual Congress 2011 - Experimental modulation of airway inflammation
Year: 2011
Proteinase inhibition regulates the anti-tumor activity of PAI-1 towards lung and prostate cancer cells
Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics
Year: 2011
Elevated endogenous thrombin potential in patients with lung cancer
Source: Eur Respir J 2003; 22: Suppl. 45, 199s
Year: 2003
Usefulness of selective neutrophil elastase inhibitor, sivelestat, in ALI patients with SIRS
Source: Annual Congress 2012 - How to use technology to provide better critical care
Year: 2012
Plasminogen activator inhibitor type 1 (PAI-1) is a negative regulator of lung cancer cells growth due to its anti-proteinase activity
Source: Annual Congress 2008 - Novel targets in the molecular pathology of lung cancer and COPD
Year: 2008
Secretory leukocyte proteinase inhibitor in lung cancer: an immunohistochemical and serological study
Source: Eur Respir J 2006; 28: Suppl. 50, 388s
Year: 2006
Proapoptotic and anti-proliferative effect of the stable plasminogen activator inhibitor type 1 (PAI-1) mutant on the lung cancer and endothelial cells
Source: Annual Congress 2009 - What is new in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease?
Year: 2009
Antithrombin plus alpha–1 protease inhibitor does not affect pulmonary inflammation and coagulation in a ‘double-hit’ lung injury model
Source: International Congress 2018 – Preclinical and clinical studies of critical illness
Year: 2018
In vitro and in vivo characterisation of the novel neutrophil elastase inhibitor BI 1323495
Source: Virtual Congress 2020 – Scientific advances in airway pharmacology
Year: 2020
Circulating d-Dimer lysozyme and angiotensin-converting enzyme in active sarcoidosis
Source: Eur Respir J 2001; 18: Suppl. 33, 196s
Year: 2001
Development of a novel immunoassay for the measurement of active plasmin in patients with IPF
Source: International Congress 2017 – Chronic airway disease: markers of disease impact
Year: 2017
5-lipoxygenase inhibitor therapy in IPF
Source: Annual Congress 2008 - New therapeutic strategies in idiopathic pulmonary fibrosis
Year: 2008
Association of polymorphisms in the genes of the urokinase plasminogen activation system with susceptibility to and severity of nonsmall cell lung cancer
Source: Annual Congress 2009 - Lung cancer biology
Year: 2009
The biological effect of intrapleural tissue plasminogen (tPA) activator and DNase delivery in pleural infection patients.
Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies
Year: 2018
LSC Abstract – A functional variant of secretory leukocyte protease inhibitor (SLPI) with improved anti-inflammatory activity against pulmonary infection
Source: International Congress 2015 – Immunomodulation: basic science and clinical aspects
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept